article Open AccessTop 1% cited

Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era

Cancer · 2005 · Vol. 103(4) · pp. 821–829

Bengt Nilsson(University of Gothenburg)Per Bümming(University of Gothenburg)Jeanne M. Meis‐Kindblom(University of Gothenburg)Anders Odén(University of Gothenburg)Aydin Dortok(Novartis (United States))Bengt Gustavsson(Novartis (Sweden))Katarzyna Sablinska(Novartis (Switzerland))Lars‐Gunnar Kindblom✉(University of Gothenburg)

View via DOI Full-text PDF

Abstract

GIST has been under recognized: Its incidence, prevalence, and clinical aggressiveness also have been underestimated. Currently existing risk-group stratification systems based on tumor size and mitotic rate delineate GIST patients who have a poor prognosis. Prognostication in patients with GIST can be refined using a proposed risk score based solely on tumor size and proliferative index.

Gastrointestinal Tumor Research and Treatment Gastric Cancer Management and Outcomes Gastrointestinal disorders and treatmentsGiSTMedicineIncidence (geometry)Internal medicineStromal tumorImatinib mesylatePopulationAutopsySurgeryStromal cell

MeSH terms

Imatinib MesylateAge FactorsAntineoplastic AgentsBenzamidesHumansPiperazinesPrognosisPyrimidinesRetrospective StudiesRisk FactorsDigestive System Surgical ProceduresSwedenIncidencePrevalenceSurvival Analysis